The PRWIRE Press Releases https:// 2021-02-26T19:51:33Z ELDO at the Forefront of Manufacturing Wet & Dry Wipes & Masks 2021-02-26T19:51:33Z eldo-at-the-forefront-of-manufacturing-wet-amp-dry-wipes-amp-masks By the end of 2019, China was facing the threat of COVID-19, and the family firm, ELDO decided to establish the face mask lines. Due to their good relationship and resources on the non-woven field, three fully automatic lines were built in a very short time. Each line daily output is around 120,000pcs. However, the face mask business is not only built to fight against COVID-19, ELDO’s mission is to expand the wipe business and to be the most professional and reliable wipe factory in China.    As the coronavirus disease 2019 (COVID-19) pandemic progressed, one debate raged on as to the use of face masks by individuals in the community. People often wear masks to protect themselves, but it is suggested that a stronger public health rationale is source control to protect others from respiratory droplets. This approach is important because of possible asymptomatic transmissions.     There are mechanistic reasons for covering the mouth to reduce respiratory droplet transmission and, indeed, cough etiquette is based on these considerations and not on evidence from clinical trials.    Over 20 years ELDO’s business has grown through providing a very high level of service, quality and dedication to their customer needs, and their comprehensive range of products saves you time and money and enables you to buy from one supplier. They now supply their high-quality products around 1000 containers annually to more than 55 countries.     Finally, mass masking is underpinned by basic public health principles that might not have been adequately appreciated by authorities or the public. First, controlling harms at source (masking) is at least as important as mitigation (handwashing). The population benefits of mass masking can also be conceptualised as a so-called prevention paradox—ie, interventions that bring moderate benefits to individuals but have large population benefits.    The ELDO team look forward to offering you their outstanding service in the near future, and for more information on single use wet wipes, protective face masks and disposable latex gloves please go to .   Microba Life Sciences joins renowned Microbiome Therapeutics Innovation Group to drive life-saving therapeutics forward 2021-02-22T22:39:52Z microba-life-sciences-joins-renowned-microbiome-therapeutics-innovation-group-to-drive-life-saving-therapeutics-forward AUSTRALIA - Leading biotech Microba Life Sciences has joined the ranks of prominent microbiome therapeutic, biopharmaceutical and bioscience companies as a new member of the Microbiome Therapeutics Innovation Group (MTIG). Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission of accelerating microbiome therapeutic development to advance medicine. The addition of Microba brings MTIG’s membership to six companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products, as well as a new voice in Microba’s CEO Blake Wills as a new Director of MTIG’s Board. A leader in gut microbiome analysis and precision microbiome science, Microba’s expertise in combining accurate measurement of the gut microbiome with a human-first, data-driven approach to therapeutic discovery is being used to develop microbiome-derived treatments as new solutions to human health problems. Joining other members Seres Therapeutics, Rebiotix, Siolta Therapeutics, Takeda and Vedanta Biosciences, Microba will add to the collective voice of the group which aims to address unmet clinical needs, improve clinical outcomes and reduce healthcare costs. Leveraging the status of the human microbiome as a new frontier in medical innovation, MTIG is an independent coalition of companies lending their voice to research and development of FDA-approved microbiome therapeutics and microbiome-based products. “At Microba, our mission is to develop life-enhancing therapeutics to progress medicine by harnessing the microbiome as a rich source of novel therapeutics,” said Blake Wills, Microba CEO. “Our core belief is that comprehensive and precise measurement of the human gut microbiome and our unique approach to genome-directed isolation are integral in driving new opportunities.” Chairman of MTIG, Dr Ken Blount, PhD, said that Microba’s addition to MTIG would assist in their mission to advance health globally through innovative microbiome therapeutics. “Microba Life Sciences brings a unique viewpoint as a pre-clinical biotech utilizing an innovative, data-focused approach to identifying therapeutic discoveries,” he said. “We welcome their efforts as we seek to advance the regulatory field for microbiome therapeutics.”   Ends. Gold Coast's prominent hypnotherapy practice, Moving Minds Hypnotherapy wins the 2021 ThreeBestRated® award 2021-02-19T04:29:58Z gold-coast-s-prominent-hypnotherapy-practice-moving-minds-hypnotherapy-wins-the-2021-threebestrated-award-1 Gold Coast 19/02/2021 - Moving Minds Hypnotherapy, one of the most sought after hypnotherapy practices in Gold Coast, Queensland, has won the prestigious 2021 ThreeBestRated® award. Moving Minds Hypnotherapy has been a recipient of this award for more than four times. Each year ThreeBestRated® review team conducts a rigorous 50-point inspection to rate and list the top three hypnotherapy practices on their website. Reviews, ratings, reputation, history, complaints, satisfaction, trust, cost, general excellence, etc., of the hypnotherapy practice, are evaluated using the 50-point inspection before honouring them with the award. "We are very proud to say we have been recognised on the 'ThreeBestRated®' website's list since 2017 and are sitting in the first position, for the last three years. Many people self-proclaim to be the best. But to be acknowledged by an independent, non-biased agency who also has the intention of serving the public is something we take great pride in.", said Greg Thompson, founder of Moving Minds Hypnotherapy. Moving Minds Hypnotherapy's achievement of being the best didn't happen overnight. Their remarkable journey started in 2015. Greg Thompson, the lead hypnotherapist, established Moving Minds Hypnotherapy with an aim to serve the needs of the communities of Gold Coast through hypnosis. Over the years, Greg has helped thousands of people with anxiety, depression, and weight-loss, as well as habits and addictions such as smoking, alcohol, and drugs. Greg has led his clinic to grow into a trusted practice to overcome emotional and behavioural issues. The Team In 2020, Greg Thompson added two additional hypnotherapists to his team. Both of which are trained to the highest standards. They are accredited by both the Australian Hypnotherapists Association (AHA) and The Hypnotherapy Council of Australia (HCA). The team of professionals continues to be mentored by Greg in the practice of helping people heal, grow, and overcome limiting beliefs and behaviours. All of their team members at Moving Minds Hypnotherapy are fascinated with the power of the mind and are passionate about being a force for good in the world. They said, "We feel lucky to be the people that can facilitate positive changes that often feel impossible for our clients. To see someone walk into our office crippled by anxiety or depression and has tried absolutely everything else to no avail, leave our office only an hour later, totally transformed. There are no words to describe the appreciation we feel in knowing that this is the work we do!" The Moving Minds hypnotherapists understand that everyone is different and so they tailor-adjust traditional clinical hypnotherapy and conversational hypnotherapy to get the absolute best result for their clients. They are transforming the lives of so many people across Australia through hypnosis. CONTACT INFORMATION Moving Minds Hypnotherapy Suite 1 West Wing, 2 Fortune St,  Coomera, QLD 4209 Phone: 0422 741 041 E-mail: Website: Vitalcare and Checked In Care partner to improve home care services 2021-02-16T05:38:09Z vitalcare-and-checked-in-care-partner-to-improve-home-care-services Checked in Care (CiC), the leading customer experience self-service app platform, and Vitalcare, Australia’s most trusted brand in personal emergency response services, have partnered to drive their joint visions of enabling Ageing in Place.   “Checked in Care’s underlying philosophy is to enable a better quality of life, more cost-effectively, through the innovative use of technology. The Vitalcare partnership is a major step forward in enabling seniors to age in place, at the location of their choosing” notes John Perkins, CEO of Checked in Care. “A major concern of families is whether Mum or Dad is okay, whereas the seniors wish to know that when they need help, it is at hand via a single button push. With Vitalcare’s Rosie service on the Checked in Care platform, we make this happen.”   “Enhancing communications and care, and helping to improve the lives of seniors, their families, and care teams is our mission, which is so important when so many people feel disconnected. Vitalcare is proud to partner with Checked in Care to enable better connection and quality of life for seniors. Through this partnership, clients will receive a wide range of services and support that will assist them to remain independent and safe at home, even in an emergency,” says Logan Ross, Managing Director of Vitalcare.   Together, the partnership will help family and friends better care for their loved ones who live on their own, or those who live remotely. Through the CiC app platform, the family will receive ongoing notifications about their loved ones’ wellbeing and receive alerts when their loved one’s activity declines. “With Vitalcare, we have enabled a soft button on senior’s smart devices, that will make a call to Vitalcare’s 24/7 monitoring centre, giving seniors, and their families peace of mind that help is at hand, when required”, further notes John Perkins.   “Vitalcare always put clients at the heart of its operations and is dedicated to providing quality care at any time of the day or night. Having access to Checked in Care’s simple to use app, connected to Vitalcare’s 24/7 monitoring service will help clients and their loved ones feel safe and cared for at home, providing peace of mind for everyone,” also adds Logan Ross.   Logan Ross says, “Together, we will continuously develop solutions that will integrate a broader range of services to deliver person-centred experiences and quality health outcomes in the future.”   Checked in Care and Vitalcare’s solution can support ageing in place and improve seniors’ quality of life, whilst reducing the cost of care across a wide range of NDIS, Home Care and Residential Aged Care Facility operations. Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial 2021-02-11T14:01:20Z novamind-announces-strategic-investment-in-bionomics-to-support-ptsd-clinical-trial      Cedar Clinical Research to be Evaluated to Support Phase IIb Trial of Novel PTSD Treatment TORONTO, Feb 11, 2021 - (ACN Newswire) - Novamind Inc. (CSE:NM) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has made a strategic investment of AU$827,486 (approximately CAN$810,000, the "Strategic Investment"), in Bionomics Limited ("Bionomics") (ASX:BNO)(OTCQB:BNOEF) (Germany:AU000000BNO5), a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210. BNC210 has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD).With its investment in Bionomics, Novamind joins a group of well-known investors that specialize in psychedelics and biotech: Apeiron Investments, Biotech Value Fund, Merck & Co., Mike Novogratz, and Peter Thiel, an early investor in ATAI Life Sciences.Novamind's Strategic Investment is included in Bionomics' latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the "Bionomics Financing"). Novamind will purchase a total of 5,706,800 common shares in the Bionomics Financing, at AU$0.145 per share, a 20% discount to the 30-day volume weighted average price as of February 5th, 2021. Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.Bionomics intends to evaluate Cedar Clinical Research's deep expertise in facilitating Phase I to Phase IV clinical trials for leading pharmaceutical companies, and how it may potentially serve as a research site for Bionomics' Phase IIb clinical trial examining BNC210 in PTSD patients.Cedar Clinical Research, led by Novamind's Chief Medical Officer, Dr. Reid Robison, is currently contracted for seven clinical trials with various sponsors, including leading pharmaceutical companies. Dr. Robison has led over 100 clinical trials in neuropsychiatry, researching a spectrum of psychiatric conditions, including PTSD."I'm happy to welcome Novamind as a strategic investor in Bionomics," said Dr. Errol De Souza, Executive Chairman of Bionomics. "Dr. Robison and the team at Cedar Clinical Research have unique experience related to clinical trials for mental health therapeutics."Yaron Conforti, CEO and Director of Novamind, added, "We are pleased to participate in Bionomics' financing to support the development of its novel drug candidate for the treatment of PTSD. Cedar Clinical Research has unique expertise in PTSD research, and we look forward to the opportunity to contribute to the development of BNC210."To learn more about Cedar Clinical Research, please visit BionomicsBionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada). To learn more, please visit NovamindNovamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit InformationNovamindYaron Conforti, CEO and DirectorTelephone: +1 (647) 953 9512Bill Mitoulas, Investor RelationsEmail: bill@novamind.caForward-Looking StatementsThis news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.SOURCE: Novamind Inc. Pfizer and BioNTech Achieve Approval by Medsafe For Their Vaccine Against COVID-19 2021-02-03T01:38:37Z pfizer-and-biontech-achieve-approval-by-medsafe-for-their-vaccine-against-covid-19 AUCKLAND, NEW ZEALAND [3 February 2021] — Pfizer New Zealand and BioNTech today welcomed the drug safety regulator Medsafe in New Zealand granting Provisional Consent for their COVID-19 mRNA vaccine COMIRNATY™. Pfizer is the Market Authorisation Holder in New Zealand. The distribution of the vaccine in New Zealand will be prioritised by the Ministry of Health according to the populations identified in guidance from the New Zealand Government's Immunisation Implementation Advisory Group (IIAG). “Today’s Provisional Consent in New Zealand marks an historic moment in the fight against COVID-19. It further affirms Pfizer’s commitment to deliver on its promise to safely bring to New Zealanders a high quality vaccine against this virus,” said Anne Harris, Pfizer New Zealand Managing Director. “We commend Medsafe for its careful assessment of COMIRNATY. “Being granted Provisional Consent means that Pfizer-BioNTech will continue to provide Medsafe with further data from our clinical trials, and we look forward to working with Medsafe to share these data and information as they become available,” Ms Harris said. “We thank both the New Zealand Government and the Ministry of Health for their strong partnership to bring our vaccine to New Zealanders. “We are proud to be part of this breakthrough, which was made possible through unparalleled collaboration between companies, governments, regulators, public health bodies, and the academic and scientific communities coming together urgently to find solutions to the pandemic”, Ms Harris said.   “It is encouraging to see that our mRNA vaccine is now approved in New Zealand. The number of countries authorising the use of our vaccine is steadily increasing. This is important in order to support addressing this pandemic,” said Sean Marett, Chief Business Officer and Chief Commercial Officer at BioNTech.  Medsafe’s decision is based on a rolling submission, including data from the Phase 3 clinical study, which demonstrated a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol. Efficacy was consistent across age, gender, race and ethnicity demographics, with an observed efficacy in adults age 65 and over of more than 94%. In the trial, BNT162b2 was generally well tolerated with no safety concerns reported by the Data Monitoring Committee to date. Today’s decision also is based on a review of Pfizer’s and BioNTech’s Chemistry, Manufacturing and Control (CMC) data for BNT162b2. Pfizer and BioNTech previously announced on 12 October 2020 an agreement with the New Zealand Government to supply 1.5 million doses of its mRNA-based vaccine COMIRNATY™ to 750,000 New Zealanders, once approved. Dose deliveries will occur throughout 2021 in accordance with terms of the supply agreement.  To date, the vaccine has been granted a conditional marketing, emergency use authorisation or temporary authorisation in more than 50 countries worldwide. Manufacturing and Delivery Capabilities Pfizer and BioNTech continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to country authorisation or approval, to help ensure it can reach those most in need as quickly as possible. The companies are leveraging leading vaccine manufacturing and distribution capabilities to quickly scale, manufacture and distribute large quantities of the vaccine at high quality, complementing the mRNA manufacturing expertise of BioNTech gained over almost a decade. Pfizer has a 171-year track record of researching, developing, manufacturing and delivering innovative medicines and vaccines to patients in need. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Pfizer Disclosure Notice  Information contained in this release is as of 3 February 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, Provisional Consent in New Zealand, regulatory submissions, including pending requests for emergency use authorization and other marketing applications, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply), involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary or clinical data (including the Phase 3 data), including the possibility of unfavourable new preclinical clinical or safety data and further analyses of existing preclinical or clinical or safety data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations upon commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy,  safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any other biologics license and/or emergency use authorization applications may be filed in any particular jurisdictions for BNT162b2 or any other potential vaccine candidates, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labelling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and About BioNTech  Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit BioNTech Forward-looking Statements  This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer regarding a COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected time point for additional readouts on trial data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimate for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.  For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. Industry OneCARD™ Introduces Track and Trace for COVID-19 Immunisations 2021-02-02T06:01:48Z industry-onecard-introduces-track-and-trace-for-covid-19-immunisations Industry OneCARD™ is leading the way to create a high Industry standard for supporting businesses to maintain compliance against WHS legislation by providing a simple but effective way of managing employee training and licensing requirements. The company’s newest innovation is the ability to track and trace immunisations, including the COVID-19 vaccine. The service is available Industry OneCARD™ members and due to the wider need Industry OneCARD™ Vac Track and Trace service has now been expanded to include non-members and individuals.  Existing Industry OneCARD™ members will automatically receive Vaccination Track and Trace as part of their current membership. Non- members and individuals will be charged a small admin fee.  Anyone that needs to provide proof of immunization can do so. The records are visible via scan by any mobile device and all information is maintained to the highest levels of safety and security. Simply provide documentation that includes the date, brand and batch number signed by a health provider. The data will be uploaded to members Industry OneCARD™ or a non-member or individuals Vac OneCARD. Reminders and alerts will be set when the second vaccination is required and any boosters that may be needed in the future for COVID-19 vaccination tracking. In the future Immunisations records may be required for anyone traveling or working outside the country, but they may also be a requirement to provide proof of Immunisation when going to work, attending a large gathering etc.  The instance of outbreaks, severity, restrictions, and lockdowns in connection with the pandemic varies considerably due to the unpredictability of the virus. COVID-19 immunisation tracking with the Industry OneCARD™ provides a single, reliable resource for ensuring compliance and reminders. The new ability is especially beneficial for healthcare professionals and essential workers. Both groups may be needed to provide essential services or assistance in areas other than their normal work environment. Vaccination tracking Australia ensures they can move about more freely to where they’re needed most. Mass vaccinations are expected to begin for Australians in February 2021. The goal is to vaccinate 80,000 people within the first week and quickly accelerate vaccination numbers from there. With new variants of the virus occurring around the globe, vaccine tracking Australia is essential so individuals can continue to work and live safety, while protecting the health of others. The Vaccination Track and Trace service is now available for Industry One CARD members and coming soon for individuals and non-members.  Media Contact Industry OneCARD™ Kareena Waters – Managing Director  Phone: +61 417760224 Website: Sydney Chiropractor Celebrates World Spine Day 2021-02-02T01:04:44Z sydney-chiropractor-celebrates-world-spine-day Ryde, NSW, Australia - 15 October 2020 - Sydney chiropractic clinic Ryde Chiropractic will be celebrating its first World Spine Day with free pre-consultations to raise awareness for spinal health care. Taking place on October 16 each year, World Spine Day highlights the burden of spinal pain and disability around the world. Ryde Chiropractic’s free pre-consultations will be available to all visiting patients with no obligations.  In alignment with the purpose of World Spine Day and as part of his consultations, Dr. Anthony Leong (Chiropractor) will be answering questions on spinal problems, potential treatment plans and other back care complications. “Your spine is your lifeline. Problems that stem from poor habits, poor posture or injury can have far reaching effects in someone’s life and may decrease quality of life.” Since the start of the coronavirus pandemic, Dr. Leong has noticed the increased influx of spinal pain patients into his clinic as a direct result of working from home initiatives and a lack of physical exercise. Working as part of World Spine Day’s ‘Back on Track’ theme, Dr. Leong hopes his free pre-consultations will encourage patients to seek any necessary spinal treatment and chiropractic care. “Those who visit Ryde Chiropractic will receive any necessary professional advice about their posture, habits and spinal health as well as as well as any necessary hands on care and rehabilitation. This is what we love to focus on everyday ,” said Dr. Leong. World Spine Day will fall on the 16th of October and will be organised by the World Federation of Chiropractic. The day aims to highlight the burdens of spinal pain and promote treatment strategies for spinal disabilities. In Australia, World Spine Day is hosted by the Australian Chiropractic Association. Find out more about World Spine Day here. -ENDS- About Ryde Chiropractic: Ryde Chiropractic, founded Dr. Anthony Leong (Chiropractor), has over 18+ years of ‘hands-on’ chiropractic experience, having helped thousands of patients reduce their pain and improve their health. Official Disclaimer: “Dr. Anthony Leong (Chiropractor) from Ryde Chiropractic is an Australian Health Practitioner Registration Agency (AHPRA) registered Doctor of Chiropractic (provider number: CHI0001655060.” Contact Info: Name: Dr. Anthony Leong (Chiropractor)Organisation: Ryde ChiropracticAddress: 3/455 Blaxland Rd, Denistone East, NSW 2112Website: Blood cancers climb ranks to now become second most diagnosed cancers and second highest cause of cancer-related deaths in Australia 2021-02-01T01:33:27Z blood-cancers-climb-ranks-to-now-become-second-most-diagnosed-cancers-and-second-highest-cause-of-cancer-related-deaths-in-australia-4 The Leukaemia Foundation is today releasing alarming new figures confirming that blood cancers combined are now the second most diagnosed cancers in Australia, and the second most common cause of cancer-related deaths in the country[i].   After an extraordinary 30% increase in incidence rates of blood cancer over the past decade, these latest rankings come at a time when the organisation is also experiencing a massive 30% increase in demand for its services as more Australians living with blood cancer than ever before reach out for support.   On his first day as the Leukaemia Foundation’s newly-appointed CEO, Chris Tanti says this sobering combination makes the 2021 World’s Greatest Shave campaign, launching today, one of the most critically important in the organisation’s history to help Australia’s leading blood cancer charity keep pace.   “These new findings confirm that we really are dealing with some of the nation’s most diagnosed and deadly cancer killers – and that there is simply no time to waste to cure and conquer blood cancer,” he said.   “Last year alone, 17,321 people were diagnosed with a blood cancer such as leukaemia, lymphoma or myeloma, and we know that come 2035, more than twice as many Australians will be diagnosed with one annually – which means more people than ever are going to be seeking the Leukaemia Foundation’s support into the future[ii].   With the Leukaemia Foundation continuing to face a devastating shortfall of donations due to the impact of COVID-19, those taking part in this year's World’s Greatest Shave will make an extraordinary difference by fundraising toward a collective target of $15 million in 2021.   Now in its 23rd year, the campaign is the single biggest source of revenue for the organisation since it started in 1998 as Shave for a Cure. “There has never been a more vital time to get behind the World’s Greatest Shave to raise much-needed funds for the Leukaemia Foundation to continue answering the call of families across the country impacted by this complex set of diseases," Mr Tanti said.   In Australia today, 47 Australians will be told they have a blood cancer, and 15 people will lose their battle with the disease, with blood cancer claiming the lives of more than 5,600 people each year. Blood cancer also continues to remain the most commonly diagnosed childhood cancer accounting for over 40% of all diagnoses[iii].   “As we lead into World Cancer Day this Thursday, we gain a clearer understanding through these latest figures the enormous size, scale and impact of blood cancer. You only have to mention leukaemia, lymphoma or myeloma and you’ll soon come across someone who’s faced blood cancer themselves, or who knows and loves someone who’s been diagnosed,” Mr Tanti said.   Blood cancer does not discriminate. It can develop in anyone, can occur at any age and at any stage of life across all states and territories, from children to adolescents and young adults to working adults with families and older Australians. Sadly, there are no screening programs available for blood cancers and there is no way to prevent blood cancer through lifestyle change.   Mr Tanti said the Leukaemia Foundation is bracing for a spike in blood cancer diagnoses as COVID-19 restrictions ease and more Australians seek health check-ups, potentially receiving the gutting news that they have blood cancer in the process.   “Blood cancer symptoms can sometimes be subtle or similar to other conditions such as a virus, often making it a silent disease that can be tricky to catch - but if it remains unchecked, the consequences can be devastating,” he said.   “The reality is blood cancer doesn’t stop for a global pandemic and we know for every day since COVID-19 began, another 47 Australians would have developed blood cancer even if they don’t yet know it.   “That is why we are urging Australians not to postpone trips to their doctor and to address any health concerns immediately. Ongoing symptoms such as recurrent infections, increased fatigue or bruising or enlarged lymph nodes should be urgently discussed with your GP.”   Money raised from World’s Greatest Shave not only supports families impacted by blood cancer, but it also helps research scientists continue their search for better ways to diagnose and treat blood cancer more effectively.   “The Leukaemia Foundation will not stand idly by while blood cancer continues to take so many lives. It’s time to turn the tables on blood cancer and to realise our goal of zero lives lost to blood cancer by 2035. We urge all Australians to join with us in taking a stand against blood cancer by rallying together, signing up to World’s Greatest Shave, and bravely shaving their head in 2021,” Mr Tanti said.   Officially ramping up to ‘Shave Week’ between March 10-14, join the fight against blood cancer and register by downloading the app, signing up online at or call 1800 500 088 for more information. #worldsgreatestshave  #shaveforacure  #shavechallenge  *ENDS* Source: Australian Institute of Health and Welfare [i] [ii] [iii] For further information, images, footage or to interview a Leukaemia Foundation spokesperson or an Australian impacted by blood cancer, please email or call 0427 251 452 (NSW, SA, WA, TAS) and 0429 850 562 (QLD, VIC, ACT, NT) ELDO Advise on The Basics on How to Properly Wear a Mask in COVID-19 2021-01-30T05:49:29Z eldo-advise-on-the-basics-on-how-to-properly-wear-a-mask-in-covid-19 Mask manufacturers, ELDO are happy to pass on some advice on how to properly wear a mask in COVID-19, explaining that masks  should be used as part of a comprehensive strategy of measures to suppress transmission and save lives; the use of a mask alone is not sufficient to provide an adequate level of protection against COVID-19.    If COVID-19 is spreading in your community, stay safe by taking some simple precautions, such as physical distancing, wearing a mask, keeping rooms well ventilated, avoiding crowds, cleaning your hands, and coughing into a bent elbow or tissue. Check local advice where you live and work. Do it all!    Make wearing a mask a normal part of being around other people. The appropriate use, storage and cleaning or disposal of masks are essential to make them as effective as possible.    Clean your hands before you put your mask on, as well as before and after you take it off, and after you touch it at any time.   • Make sure it covers both your nose, mouth and chin.  • When you take off a mask, store it in a clean plastic bag, and every day either wash it if it’s a fabric mask, or dispose of a medical mask in a trash bin. • Don’t use masks with valves. Masks with vents or exhalation valves are not advised because they allow unfiltered breath to escape the mask.    Regarding children, there may be local requirements for children aged 5 years and under to wear masks, or specific needs in some settings, such as being physically close to someone who is ill. In these circumstances, if the child wears a mask, a parent or other guardian should be within direct line of sight to supervise the safe use of the mask.    ELDO provides a very high level of service, quality and dedication to their customer needs., and their comprehensive range of products saves you time and money and enables you to buy from one supplier, so for more information on disposable dry wipes, PE aprons and disposable sterile gloves please go to .  Aurora Cannabis and MedReleaf Australia Announce Strategic Agreement 2021-01-27T22:22:44Z aurora-cannabis-and-medreleaf-australia-announce-strategic-agreement     January 27, 2021                                                                              NYSE | TSX: ACB   Aurora Cannabis and MedReleaf Australia Announce Strategic Agreement Broadest Medical Cannabis Product Range in Australian Market Edmonton, AB – January 27, 2021– Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has entered into a strategic agreement with MedReleaf Australia (“MedReleaf”). The companies have signed a five-year supply agreement, which provides for MedReleaf to act as the exclusive supplier in Australia of Aurora’s MedReleaf, CanniMed and Aurora brands. Products covered by the agreement will be EUGMP certified and include dried flower, oils, and soft gels, as well as future products employing new delivery mechanisms. The agreement does not require or include any capital investment by Aurora. MedReleaf Australia, in which Aurora holds a 10% ownership stake, is a fully licenced, private company operating in the Australian medical cannabis sector since 2016. MedReleaf and Aurora currently supply products to the Australian medical cannabis system. This agreement will advance that offering and extend availability of high-quality, medical cannabis to patients. MedReleaf is one of the six founding members of the trade association Medicinal Cannabis Industry Australia (MCIA). "We are pleased to have established a long-term strategic relationship with MedReleaf to exclusively distribute the Aurora, CanniMed and MedReleaf brands in Australia,” said Miguel Martin, CEO of Aurora. “The team at MedReleaf have created an asset-light, sustainable growth platform in Australia to assist physicians, pharmacists and patients across the country in accessing the high-quality range of Aurora cannabis medicines." Russell Harding, CEO of MedReleaf added, “Australia’s medical cannabis system is well designed, well regulated, and among the fastest growing in the world. Our strategic supply agreement with Aurora ensures that our patients will have reliable access to cannabis medicines with a worldwide reputation for quality and in accordance with the stringent requirements of Australia’s Therapeutic Goods Administration. To support our companies’ shared objectives in the Australian market, we will focus with diligence and discipline on continuing to expand our patient and prescriber base.” About Aurora Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB” and is a constituent of the S&P/TSX Composite Index. For Media:                                                                For Investors: Michelle Lefler                                                           ICR, Inc. VP, Communications & PR                                        Investor Relations                       Forward Looking Statements This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the supply of cannabis products to MedReleaf Australia. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward looking statements are based on the opinions, estimates and assumptions of management in light of management's experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 24, 2020 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at and filed with and available on the SEC’s website at, any of which could cause the Company to change its use of proceeds from the Offering. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. High level roundtable on 28 January to examine trust in COVID-19 vaccine supply chain 2021-01-27T10:45:58Z high-level-roundtable-on-28-january-to-examine-trust-in-covid-19-vaccine-supply-chain MEDIA ALERT: Public health officials and pharmaceutical executives will hold an on-the-record roundtable session to examine trust in the COVID-19 vaccine supply chain. Leaders from the WHO, the World Bank, Deloitte, J&J and GS1 to explore early learnings and what must be done moving forward to ensure successful global distribution and administration of the COVID-19 vaccines. WHAT:This GS1 Healthcare Executive Dialogue will bring together senior leaders from the healthcare industry and major organisations across the life sciences and healthcare value chain to discuss some of the key challenges, opportunities and early learnings presented by the distribution of the COVID-19 vaccines across the globe. The event will be on the record and will include time for media Q&As.A new Deloitte white paper highlights the “urgent need” for common standards across the healthcare supply chain as the world gears up for the largest deployment of vaccines in history. Global public health officials have been strongly arguing for a while for the “need to trace every vaccine dose”. You can access Deloitte’s report Securing trust in the global COVID-19 supply chain here and GS1’s press release here. WHO:Lisa Hedman, Group Lead, Supply and Access to Medicines, World Health OrganizationGregory Reh, Global Life Sciences and Healthcare Leader, Deloitte Tom Woods, Chairman of the Global Steering Committee Assurance of Health Products for the World BankTjalling van der Schors, Hospital Pharmacist at Dijklander Hospital, Board Member at the European Association of Hospital Pharmacists, NetherlandsWHEN:Thursday, 28 January, 21:00-22:00 AESTWHERE:The event can be accessed via video link. Registration is required. More information and registration forms can be found here. GS1 Australia media contact:Wendy McWilliams, WMC Public Relations Pty Ltd. Tel: 03 9803 2588 / 0421 364 665 Microba partners with UQ to tackle Parkinson's Disease by mining the gut microbiome 2021-01-22T01:32:02Z microba-partners-with-uq-to-tackle-parkinson-s-disease-by-mining-the-gut-microbiome Brisbane-based biotech Microba have partnered with researchers from The University of Queensland’s (UQ) Faculty of Medicine to develop new treatments and biomarkers for Parkinson’s disease by investigating changes in the gut bacteria of those with the disease. Parkinson’s disease is the second-most prevalent neurodegenerative disease worldwide, with more than 10 million suffering from the disease at varying degrees. The disease is characterised by the loss of brain cells that produce dopamine. There are currently no early diagnostics, and treatments only assist to manage some symptoms. Research is increasingly pointing towards the gut microbiome as playing a role in the development of Parkinson’s, with evidence showing that changes in gut function often come many years before the onset of symptoms such as tremors. Microba’s expertise in analysing the gut microbiome with leading sequencing technology called metagenomics will be used by UQ researchers to study changes in the microbiome with the aim of identifying biomarkers for earlier diagnosis and developing new therapeutic interventions. The partnership will involve a combination of human studies in Parkinson’s disease patients and work in animal models.   The partnership’s first clinical trial, funded by the Queensland Government’s Advance Queensland Program, is set to commence in 2021 at multiple sites in Queensland. It will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms such as constipation in Parkinson’s disease patients. Microba Co-founder Professor Gene Tyson said this project would take an important step towards advancing research on the gut microbiome in neurodegenerative diseases. “We believe that this partnership will uncover disease-related signals in the microbiome that have not been seen before. We are excited to apply Microba’s leading measurement and analysis tools to enable discovery in this debilitating disease” Research Lead and Group Leader in Clinical Neuroscience at the Translational Neuroscience Research Group, Dr Richard Gordon, said that the team were excited to work with Microba for this important research program. “The microbiome represents a new frontier in our understanding of Parkinson’s. With Microba’s expertise we hope to gain unprecedented insights into the functional role of the microbiome in the disease process to guide our quest for new treatments and biomarkers for early diagnosis,” he said. Microba continues to work on developing diagnostics and therapeutics derived from the gut microbiome in the areas of Inflammatory Bowel Disease (IBD) and Immuno-Oncology. Ends. To ensure safety and trust in COVID-19 vaccination, Deloitte report urges rapid adoption of GS1 standards and barcodes 2021-01-14T19:55:20Z to-ensure-safety-and-trust-in-covid-19-vaccination-deloitte-report-urges-rapid-adoption-of-gs1-standards-and-barcodes As governments and businesses around the world face one of the most significant challenges in history – an unprecedented rapid mass development, distribution, and administration of Covid-19 vaccines – a new report issued by Deloitte points to universal adoption of global standards across the healthcare supply chain as an urgently needed solution to enable fast, efficient, and safe distribution. Global public health officials have reinforced those sentiments, with Tom Woods, Chairman of the Global Steering Committee for Quality Assurance of Health Products for the World Bank, calling for the adoption of common standards including barcode scanning, “the most important and under-discussed element in preventing vaccine distribution failures and ensuring traceability and patient safety in the COVID-19 vaccination campaign.”The Deloitte study, “Securing Trust in the Global COVID-19 Supply Chain,” argues that, in addition to industry collaboration and transparent communication, “embracing GS1 standards adds an element of trust at all levels of the supply chain – a trust that ultimately extends to the patients themselves”. GS1 global standards enable pharmaceutical manufacturers, distributing companies and healthcare providers to follow protocols and safety measures critical to ensuring public trust and confidence, both in the vaccine itself and the ability to roll out vaccinations safely.Barcodes carrying GS1 standards uniquely and securely identify medical products, including vaccines, from laboratories and clinical trials to point of administration. GS1 standards bring transparency and help to improve supply chain coordination, decreasing the risk of vaccine diversion, date expiration and fake vaccines proliferation. While the adoption of GS1 standards continues to expand in the healthcare field, they are not yet universally applied. The Deloitte study calls vaccine identification information (such as product identifier, lot number, and expiration date) “essential for healthcare providers to administer vaccines with confidence,” noting that, “the WHO recommends that all vaccines be identified with this data in a standardised barcode.” GAVI and UNICEF have also required the use of GS1 standards on the secondary packages of vaccines.Miguel Lopera, President and CEO at GS1’s Global Office noted, “an unprecedented level of research, collaboration and investment has brought hope in the form of Covid-19 vaccines. The world now faces, however, an enormous distribution and administration challenge where global identification standards have a critical role to play. Countries around the world are implementing massive vaccination campaigns under enormous time pressure, all while the virus continues to kill thousands of people every day. Global standards can help to relieve the pressure on the healthcare industry and reduce the chances for error. GS1 stands ready to help all stakeholders succeed in this critical operation.”Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte, added, “For vaccine developers, healthcare stakeholders and society at large, the level of transparency and public trust will determine Covid-19 vaccine acceptance and confidence. The continued adoption of global standards from organisations like GS1 are helping to instill that confidence in the Covid-19 vaccines.” Today more than 70 countries have healthcare regulations or trading partner requirements for which industry uses GS1 standards. These countries rely on GS1 DataMatrix two-dimensional (2D) barcodes that can encode vaccine identification information to help reduce errors and enable traceability. As some countries are experiencing tracking difficulties linking vaccines to patients at point of administration, the Deloitte report notes that “it is important to identify and label the vaccines capturing precisely which patient received which vaccine, and when.” Globally unique identification and GS1 barcoding can support that critical task.Further information can be found on GS1 HealthcareGS1 Australia works in Healthcare to support adoption and implementation of interoperable GS1 standards within the Australian healthcare industry to enhance patient safety, and operational and supply chain efficiencies. Our global community brings together healthcare stakeholders and experts to lead the successful development and implementation of global GS1 standards and guidelines. Evidence available from healthcare industry implementations shows that GS1 identification, data capture and data sharing standards deliver tangible benefit to all stakeholders - pharmaceutical and medical device manufacturers, wholesalers, distributors, group purchasing organisations, hospitals, pharmacies, logistics providers, solution providers, governmental and regulatory bodies, trade associations and most importantly patients and consumers of healthcare.For more information about GS1 standards in Australian healthcare, visit the GS1 Australia website and follow us on Twitter gs1au_health and LinkedIn gs1-australia.GS1 media contactCatherine KoetzIndustry Manager – HealthcareGS1 AustraliaD +61 3 9550 3403M +61 4 3456 1501E ELDO Talk About Wearing Face Coverings at Alert Level 1 in NZ 2021-01-02T09:45:28Z eldo-talk-about-wearing-face-coverings-at-alert-level-1-in-nz As we are all aware, at Alert Level 1, there is still a risk of COVID-19 returning to the community, and ELDO encourage you to wear face coverings on public transport and when you cannot maintain physical distance in crowded indoor places, like in supermarkets.    You legally must wear a face covering when you’re travelling on a domestic flight anywhere in New Zealand  — this does not include private flights, so be prepared by having a supply of face coverings for everyone who usually lives in your household, and add some to your household emergency kit.    In Auckland, face coverings legally must be worn on all public transport to, from and through Auckland — including on long-distance bus and train journeys, as well as Auckland ferries. Face masks must also be worn by Auckland taxi and ride-share drivers — while it’s not compulsory for passengers to wear them, we strongly encourage you  to.    People often wear masks to protect themselves, but it is suggested that a stronger public health rationale is source control to protect others from respiratory droplets. This approach is important because of possible asymptomatic transmissions. There are mechanistic reasons for covering the mouth to reduce respiratory droplet transmission and, indeed, cough etiquette is based on these considerations and not on evidence from clinical trials.    Finally, mass masking is underpinned by basic public health principles that might not have been adequately appreciated by authorities or the public. First, controlling harms at source (masking) is at least as important as mitigation (handwashing). The population benefits of mass masking can also be conceptualised as a so-called prevention paradox—i.e., interventions that bring moderate benefits to individuals but have large population benefits.    The ELDO team look forward to offering you their outstanding service in the near future, and for more information on disposable PE aprons, disposable surgical face masks and buying surgical masks please go to .